Craft

ANI Pharmaceuticals

Stock Price

$63.7

2024-06-28

Market Capitalization

$1.3 B

2024-06-28

Revenue

$486.8 M

FY, 2023

ANI Pharmaceuticals Summary

Company Summary

Overview
In two facilities with combined manufacturing, packaging and laboratory capacity exceeding 170,000 sq. ft., ANI develops and manufactures liquid, powder and oral solid dose products, including those requiring containment. The Company also performs contract manufacturing for some of the largest and most respected pharmaceutical companies in the world. The fully-cGMP qualified facilities boast state-of-the-art analytical and stability laboratories for its rapidly expanding research and development program. 
Type
Public
Status
Active
Founded
1996
HQ
Baudette, MN, US | view all locations
Website
http://www.anipharmaceuticals.com
Cybersecurity rating
ESG rating
40-49 out of 100|View all ESG data
Sectors

Key People

  • David B. Nash, Director

    • Ori Gutwerg, Senior Vice President of Generics

      • Antonio Pera, Director

        • Nikhil Lalwani, Director and President and CEO

          LocationsView all

          3 locations detected

          • Baudette, MN HQ

            United States

            210 Main St W

          • Baudette, MN

            United States

            455 Idc Rd SW

          • Oakville, ON

            Canada

            400 Iroquois Shore Rd

          ANI Pharmaceuticals Financials

          Summary Financials

          Revenue (Q1, 2024)
          $137.4M
          Net income (Q1, 2024)
          $18.2M
          Cash (Q1, 2024)
          $228.6M
          EBIT (Q1, 2024)
          $20.3M
          Enterprise value
          $1.4B

          Footer menu